Alvine Pharmaceuticals, Inc. Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease
10/29/2013 10:04:04 AM
SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, today announced that the first randomized study patient was dosed in the CeliAction Study™, a phase 2b study of its lead clinical candidate, ALV003, which is in development for the treatment of patients with celiac disease. ALV003 is an orally administered mixture of two gluten-specific proteases shown in vitro to degrade gluten, the primary immunologic trigger for celiac disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by